Baudax Bio to Present at NobleCon18 Investor Conference
April 13 2022 - 8:00AM
Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on
commercializing and developing innovative products for acute care
settings, today announced that Gerri Henwood, the Company’s
President and Chief Executive Officer, will present at the Noble
Capital Markets’ 18th Annual Investor Conference (NobleCon18),
taking place in Hollywood, Florida on Wednesday, April 20, 2022, at
3:30 p.m. Eastern Time.
A webcast of the presentation will be available
the following day on the “Events” page within the investors section
of the Baudax Bio website at
https://www.baudaxbio.com/news-and-investors. The webcast will be
archived on the company’s website, the NobleCon website, and on
Channelchek.com for 90 days following the event.
There is also the opportunity to meet with Ms.
Henwood at two breakout sessions scheduled for Wednesday, April 20,
2022, at 12:15 p.m. ET and Thursday, April 21, 2022, at 10:45 a.m.
ET.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on commercializing and developing innovative products for acute
care settings. ANJESO is the first and only 24-hour, intravenous
(IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for
the management of moderate to severe pain. In addition to ANJESO,
Baudax Bio has a pipeline of other innovative pharmaceutical assets
including two novel neuromuscular blocking agents (NMBs) and a
proprietary chemical reversal agent specific to these NMBs. For
more information, please visit www.baudaxbio.com.
CONTACT:
Investor Relations Contact:
Argot PartnersSam Martin / Kaela Ilami(212)
600-1902baudaxbio@argotpartners.com
Media Contact:
Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Sep 2023 to Sep 2024